Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06471712Phase 1Completed

Clinical Study of 18F-LNC1007 Injection PET/CT

Role: lead

NCT05723640Phase 1Completed

The Safety and Dosimetry Study of 177Lu-LNC1004 Injection

Role: lead

NCT06463782Phase 1Completed

Clinical Study of 68Ga-LNC1007 Injection PET/CT

Role: lead

NCT06237491Phase 1Not Yet Recruiting

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Role: lead

NCT06416852Phase 3Not Yet Recruiting

Clinical Study of 18F-Alfatide Injection PET/CT

Role: lead

All 5 trials loaded